-
Obesity drugmaker Novo Nordisk plunges as it cuts forecasts again
Novo now expects 2025 sales growth of 8 per cent-14 per cent in local currencies, down from its previous 13 per cent-21 per cent forecast range. It also lowered its operating profit growth estimate to 10 per cent-16 per cent, from 16-24 per cent previously.
-
SB43154 drug used in cancer research shows promise against COVID-19 in preclinical studies: Scientists
-
Sarepta resumes shipping of gene therapy Elevidys to patients who can walk
-
Torrent Pharmaceuticals plans Semaglutide rollout post patent expiry
-
India’s Reality Check: Can We Leapfrog from Generics to Innovation Like China Has?
Advertisement
Advertisement
